Pharmaceuticals Malaysia

Malaysia Dengue Vaccines Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Malaysia Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.0 Mn Placeholder estimate
Estimate 2025 $1.2 Mn 0.2% of the global market
Projected 2034 $6.1 Mn 427.7% Adds $5.0 Mn over 9 forecast years
CAGR 2025–2034 20.3% Faster than 87% of 180 Pharmaceuticals markets here
Key players 5
  • Malaysia is 0.16% of the global market.
  • In APAC, the largest is China at $55.3 Mn.
  • Fastest growing: India at 22.9% a year.
  • Malaysia ranks 8th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.0 Mn — —
2025 (base) $1.2 Mn +$0.2 Mn —
2026 (forecast) $1.4 Mn +$0.2 Mn +20.3%
2027 (forecast) $1.7 Mn +$0.3 Mn +44.7%
2028 (forecast) $2.0 Mn +$0.3 Mn +74.1%
2029 (forecast) $2.4 Mn +$0.4 Mn +109.4%
2030 (forecast) $2.9 Mn +$0.5 Mn +152%
2031 (forecast) $3.5 Mn +$0.6 Mn +203.1%
2032 (forecast) $4.2 Mn +$0.7 Mn +264.6%
2033 (forecast) $5.1 Mn +$0.9 Mn +338.7%
2034 (forecast) $6.1 Mn +$1.0 Mn +427.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $720.0 Mn
  2. North America $378.9 Mn
  3. US $289.7 Mn
  4. Europe $153.8 Mn
  5. APAC $147.1 Mn
  6. Canada $56.5 Mn
  7. China $55.3 Mn
  8. Japan $39.6 Mn
  9. Latin America $29.0 Mn
  10. Germany $25.1 Mn
  11. Middle East $26.1 Mn
  12. Brazil $20.7 Mn
  13. Italy $18.2 Mn
  14. France $17.6 Mn
  15. UK $17.2 Mn
  16. India $15.1 Mn
  17. Ecuador $14.0 Mn
  18. Africa $12.6 Mn
  19. Mexico $12.2 Mn
  20. Spain $11.7 Mn
  21. Saudi Arabia $11.2 Mn
  22. Australia $8.3 Mn
  23. New Zealand $7.5 Mn
  24. Russia $6.7 Mn
  25. South Africa $4.4 Mn
  26. UAE $4.3 Mn
  27. Egypt $2.2 Mn
  28. Philippines $1.9 Mn
  29. Hong Kong $1.2 Mn
  30. Malaysia (this report) $1.2 Mn
  31. Thailand $0.9 Mn
  32. Singapore $0.7 Mn
  33. Kenya $0.6 Mn

Report snapshot

Malaysia Dengue Vaccines Market Analysis at a glance
Market size, 2025$1.2 Mn placeholder estimate
Forecast, 2034$6.1 Mn placeholder estimate
Growth (CAGR), 2025–203420.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc., Panacea Biotec (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials6 in MalaysiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Bar chart: Malaysia Dengue Vaccines market size, 2024–2034, placeholder estimates. $1.0 Mn in 2024, $1.2 Mn in 2025 and $6.1 Mn in 2034, 20.3% CAGR.
Malaysia Dengue Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in Malaysia

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in Malaysia

Dengue Vaccines in Malaysia: rules, payment and research

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2] ClinicalTrials.gov lists 6 studies on Dengue Vaccines that are recruiting, active or about to start in Malaysia.⁠[3]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Clinical trials

6 active trials in Malaysia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Takeda Pharmaceutical Company Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 165 papers since 2021 (worldwide)

  1. CD8+ T cells and humoral immunity may mitigate the effects of antibody-dependent enhancement: implications for dengue vaccine design. Journal of virology, 2026
  2. Real-world Evidence on dengue vaccine effectiveness: a systematic review of post-licensure evidence and methodological gaps. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
  3. Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development. Vaccines, 2026
  4. Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis. Vaccines, 2026
  5. DEVELOPMENT OF A TETRAVALENT DENGUE VACCINE: GUARDRAILS NEEDED. Transactions of the American Clinical and Climatological Association, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Dengue Vaccines market in Malaysia?
Placeholder estimate: about $1.2 Mn in 2025, rising to about $6.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Dengue Vaccines market in Malaysia growing?
Placeholder estimate: about 20.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Dengue Vaccines market report cover?
The report splits the market by product (Live Attenuated Vaccines, Candidate Vaccines), age (Children, Adolescents, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Dengue Vaccines market?
Key players include Takeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc. and Panacea Biotec.
What is driving the Dengue Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.
Who regulates Dengue Vaccines in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How many clinical trials on Dengue Vaccines are running in Malaysia?
6 studies are recruiting, active or about to start in Malaysia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
How much research is published on Dengue Vaccines?
PubMed lists 165 papers on Dengue Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Dengue Vaccines in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Antimicrobial Resistance: Why Faster Testing MattersDrug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the… Needleless Connectors: Small Device, Big Infection ImpactNeedleless connectors protect staff from needle injuries, but if not cleaned they can let germs into the…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on vaccines and infectious diseases

See the topic